LX-039, Luoxin

LX-039 de Luoxin Pharmaceutical: Datos del estudio clínico de fase I presentados en ESMO 2023

Published on 08/07/2025 at 18:04 | prnewswire.co.uk

Luoxin Pharmaceutical Group Stock Co., Ltd. China Spain

View original content:https://www.prnewswire.com/news-releases/lx-039-de-luoxin-pharmaceutical-datos-del-estudio-clinico-de-fase-i-presentados-en-esmo-2023-301964625.html

en | boerse | 67981931 |